secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2024-08-29T23:59:59+00:00
Accession:  0001193125-24-209296
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Systems Announces Positive Independent Study Results for Liver-Directed Therapy in Uveal Melanoma
--------------------------------------------------------------------------------

- Study of 167 patients showed median melanoma-specific survival of 28 months with first-line liver-directed therapy vs 10 months with systemic therapy.
- Patients diagnosed 2016-2021 receiving liver-directed therapy had median MSS of 30 months, compared to 20 months for 2005-2015 cohort.
- CHEMOSAT Hepatic Delivery System was used in the study; 30 of 56 patients in 2016-2021 period received CHEMOSAT.
- Study published in Therapeutic Advances in Medical Oncology, conducted by University of Tübingen researchers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000119312524209296/0001193125-24-209296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000119312524209296/d848222d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-209296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer